Recruiting Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL NCT07493161 Conditions Ph+ ALL Locations Blood Diseases Hospital — Tianjin, Tianjin Municipality, China View Trial Details
Recruiting A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) NCT06051409 Conditions Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more Locations Ascentage Investigative Site #1044 — Birmingham, Alabama, United States Ascentage Investigative Site #1062 — Duarte, California, United States Ascentage Investigative Site #1134 — Los Angeles, California, United States Ascentage Investigative Site #1059 — Los Angeles, California, United States View all 90 locations View more locations Show fewer locations Loading locations... View Trial Details
Not Yet Recruiting Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL NCT07443488 Conditions HSCT, Ph+ ALL Locations Not specified View Trial Details
Completed Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium NCT03678454 Conditions Bone Marrow Diseases, CML, Chronic Disease, +14 more Locations ZNA Stuyvenberg — Antwerp, Belgium UZ Antwerpen — Antwerp, Belgium AZ Klina — Brasschaat, Belgium AZ St-Jan Brugge — Bruges, Belgium View all 19 locations View more locations Show fewer locations Loading locations... View Trial Details
